The federal indictment alleges that six Nevada limited-liability companies collectively operated as Protectus, supplying skin-substitute products, assisting medical providers with reimbursement claims, collecting percentage-based payments, and compensating sales representatives throughout a sprawling government-funded wound-care arrangement.
WASHINGTON, DC, August 18, 2026 — Protectus LLC and five related companies allegedly provided the corporate machinery behind a $268 million wound-care reimbursement scheme that reached Medicare, TRICARE, and CHAMPVA, according to a nine-count federal indictment naming owner Michael McMillan.
Prosecutors contend that the companies supplied skin-substitute products without requiring upfront payment, helped medical providers prepare government claims, invoiced providers only after reimbursement arrived, and calculated company collections as a percentage of each successful payment.
That operational design allegedly guaranteed participating providers substantial margins while shielding them from product costs when claims were denied, creating what the government characterizes as an illegal kickback arrangement concealed within familiar commercial language concerning rebates, discounts, contracts, and profits.
McMillan remains presumed innocent, and the indictment represents allegations rather than proven facts, while the corporate entities described throughout the charging document are not separately identified as defendants in the case caption naming McMillan alone.
Six Nevada Companies Described Collectively as Protectus
The indictment identifies Protectus LLC, Protectus Technologies LLC, Protectus Consulting LLC, Prestige Medical Consultants LLC, Velare Wound Care LLC, and Amnio ReGen Solutions LLC as Nevada limited-liability companies McMillan allegedly owned and controlled during the charged period.
Federal prosecutors collectively call those businesses “Protectus,” a drafting choice that allows the indictment to describe shared conduct without assigning every contract, invoice, claim-support task, commission, bank deposit, or provider relationship to one specific legal entity.
That collective label does not erase the companies’ separate legal existence, but it signals that prosecutors view their alleged activities as components of an integrated business system operating under McMillan’s ownership and direction across several jurisdictions.
The distinction matters because corporate affiliation alone cannot establish criminal liability, and prosecutors must connect McMillan knowingly to the charged agreements while proving how particular company records, employees, accounts, and transactions advanced the alleged scheme.
The Companies Are Central Alleged Instruments, Not Named Defendants
The indictment’s caption charges McMillan individually, rather than listing Protectus LLC or any related company as a separately indicted corporate defendant, even though the narrative repeatedly alleges that he acted through the entities and their employees.
Responsible reporting should therefore avoid declaring that every Protectus company was criminally convicted, formally charged, or judicially determined to be fraudulent, because the current public record describes their alleged role within the prosecution against McMillan.
Corporate documents can nevertheless become powerful evidence against an individual owner when invoices, internal approvals, reimbursement reports, customer communications, commission schedules, and bank movements consistently reflect instructions prosecutors attribute to that owner throughout the charged period.
McMillan’s defense may answer that employees performed lawful administrative work, separate entities pursued legitimate business purposes, commercial terminology accurately described negotiated arrangements, and selected communications cannot establish his criminal intent across almost seven years of operations.
How Prosecutors Say the Corporate System Worked
The alleged sequence began when Protectus offered physicians, podiatrists, nurse practitioners, and other medical providers skin-substitute products used to support wound closure or tissue growth for patients covered through federal healthcare benefit programs.
Protectus allegedly delivered those products without collecting an upfront purchase price, permitting a provider to use the material, submit a government claim, and wait for the payer’s adjudication before becoming obligated to pay the supplier.
When Medicare, TRICARE, or CHAMPVA denied reimbursement, prosecutors say Protectus did not charge the provider for the corresponding product, transferring the immediate denial risk away from the clinical practice under the alleged commercial arrangement.
When a government program paid, Protectus allegedly issued an invoice representing approximately sixty percent to seventy percent of the reimbursement, while the provider retained approximately thirty percent to forty percent as a predetermined financial margin.
The government characterizes that retained share as illegal remuneration intended to influence federally reimbursable product use, while the defense can argue that percentage pricing reflected legitimate commercial risk, services, collection uncertainty, or otherwise lawful contracting practices.
Why Reimbursement Was the Alleged Trigger
Reimbursement allegedly served as the central trigger connecting product cost, provider profit, company revenue, and representative compensation, making the payer’s decision more important to the transaction than a conventional fixed wholesale invoice issued upon delivery.
That sequencing allows prosecutors to argue that the businesses were organized around successful federal claims, because a denial allegedly produced no provider obligation while an approval produced both a guaranteed provider margin and a substantial Protectus collection.
Timing alone does not prove illegality, since healthcare suppliers often confront delayed payment and complicated coverage decisions, but prosecutors may combine timing with percentage terms, recruitment statements, pricing disclosures, billing assistance, and commission records to prove intent.
The defense may examine whether Protectus genuinely assumed inventory, credit, reimbursement, or collection risks that justified contingent terms, and whether providers remained free to select clinically appropriate products through independent professional judgment for individual patients.
Medicare, TRICARE, and CHAMPVA Form the Program Network
The alleged claims were paid through Medicare, the national program serving qualifying older or disabled beneficiaries, alongside TRICARE coverage for military communities and CHAMPVA benefits serving eligible spouses, surviving spouses, and children connected with qualifying veterans.
Because all three are federal healthcare programs, claims allegedly induced through prohibited remuneration could become ineligible even when a product physically existed, reached an actual patient, and possessed legitimate clinical value under appropriate circumstances.
The Justice Department’s Northern District of Texas announcement describes approximately $268 million in false and fraudulent wound-product claims and says Protectus received approximately $174 million through the challenged arrangement before authorities announced the prosecution.
Those government figures remain allegations requiring proof, and they should not be presented as final restitution, adjudicated loss, personal income, or a judicial finding that every claim suffered from identical defects across all providers and programs.
Skin Substitutes Are Legitimate Products Within a Regulated Market
Skin substitutes, sometimes described as cellular or tissue-based products, allografts, or wound grafts, can be applied over open wounds to support closure and skin growth when clinicians determine that coverage criteria and medical circumstances justify their use.
Federal programs commonly reimburse these products by square-centimeter measurements, making product dimensions, acquisition cost, wound size, billing units, documentation, and applicable coverage rules financially significant in every claim submitted by a treating provider.
The McMillan indictment should not be interpreted as a general accusation against all skin substitutes, every wound-care practitioner, or every patient treatment, because its central allegations concern remuneration, pricing representations, reimbursement-linked contracting, and resulting claims.
Clinical legitimacy and financial compliance can also raise separate questions, since a medically useful product may generate an ineligible claim if prohibited remuneration induced its purchase or a material price disclosure knowingly misrepresented the provider’s true cost.
Protectus Allegedly Assisted with Claims and Pricing Information
Prosecutors allege that McMillan and Protectus employees either billed government programs for participating providers or helped those providers submit claims, placing the corporate organization close to the information used to request reimbursement for supplied products.
The indictment says providers were required to disclose their actual acquisition price, including discounts, rebates, refunds, and other adjustments, through information identified as Box 19 on relevant Medicare claims for skin-substitute reimbursement during the charged period.
According to prosecutors, McMillan and Protectus submitted or counseled providers to submit inflated prices that did not reflect the amount practices actually paid after percentage arrangements, denial protection, and applicable adjustments were incorporated into their economic obligations.
That allegation gives the healthcare-fraud theory a document-centered foundation, because investigators can compare claim entries with contracts, invoices, credits, refunds, reimbursement notices, product records, spreadsheets, correspondence, and bank payments for each provider relationship.
The defense can contest whether the government interpreted acquisition-price requirements correctly, accounted for genuine supplier risk, selected complete records, or proved that McMillan knowingly understood a disputed box 19 figure to be materially false when submitted.
Company Invoices Allegedly Recorded the Percentage Division
One October 2022 example describes a Protectus Technologies invoice recording $53,625.60 collected by a medical provider, $16,087.68 retained by that provider, and $37,537.92 due to the company after reimbursement was received.
That arithmetic allocated seventy percent to Protectus and thirty percent to the practice, providing prosecutors with a contemporaneous business record that allegedly expressed the reimbursement division more directly than generalized marketing language or retrospective witness recollections.
Another episode involved a provider employee asking why an invoice reflected a thirty-five-percent practice profit when a new contract allegedly promised forty percent; McMillan then forwarded the message internally and requested that the invoice be corrected.
Prosecutors may argue that the correction demonstrates a deliberately negotiated profit share, while the defense may contend that transparent written percentages support an ordinary commercial explanation rather than an effort to hide unlawful remuneration from participating providers.
A Paid Claim and a Denied Claim Illustrate the Alleged Model
In May 2024, one provider allegedly notified a Protectus employee that Medicare had paid $9,024 on one skin-substitute claim while denying another, creating a side-by-side example of the arrangement’s different consequences following payer adjudication.
The employee allegedly explained that an invoice would follow once payment information arrived, and that Protectus would help resolve the denied claim after reviewing Medicare’s explanation and the underlying submission materials supplied by the practice.
After noting that Box 19 information appeared to be missing from the denied claim, the employee allegedly directed the provider to a spreadsheet for use when resubmitting the reimbursement request to Medicare.
Protectus then allegedly issued a $5,865.60 invoice for the paid claim, representing exactly sixty-five percent of the $9,024 reimbursement, while the public charging narrative describes no comparable product charge arising from the denied submission.
The government can present that sequence as a compact illustration of product supply, billing support, payer action, and contingent invoicing, although the defense may characterize the same events as transparent customer service and lawful reimbursement assistance.
Refund Activity Allegedly Followed Reversed Reimbursements
The indictment also describes a provider requesting refunds for two graft invoices after corresponding Medicare payments were being returned, with the practice allegedly promising to repay Protectus if revised claims produced reimbursement under a different company structure.
A Protectus employee subsequently advised that the refund had been processed through QuickBooks, an event prosecutors may use to argue that the provider’s purchase obligation depended fundamentally upon government payment rather than product shipment or clinical application.
The defense could describe that refund as reasonable accommodation during a billing correction, particularly if the products were delivered, reimbursement was expected after resubmission, and the governing contract permitted temporary credits following payer reversals.
This episode demonstrates why a transaction’s legal meaning cannot be determined from one label or accounting entry, because contractual terms, intent, disclosure, applicable guidance, product value, and complete communications may substantially change its interpretation.
Sales Representatives Extended the Corporate Reach
Prosecutors allege that Protectus hired sales representatives to recruit providers, explain the profit-sharing model, and encourage practices nationwide to use products distributed through McMillan’s companies when treating beneficiaries covered by the federal programs.
Representative compensation was allegedly tied directly to reimbursements generated through recruited practices, with commissions becoming payable after providers received government money and transferred the specified percentage to a Protectus company under the arrangement.
The indictment estimates that McMillan and Protectus paid approximately $27 million in representative compensation characterized as illegal kickbacks intended to induce medical referrals, orders, recommendations, or purchasing relationships across the charged nationwide network.
Sales commissions are not inherently unlawful, including in healthcare businesses, but percentage compensation tied to federal reimbursements can attract heightened scrutiny when representatives allegedly recruit clinical decision-makers with promises of guaranteed profits from product claims.
The defense may emphasize legitimate education, customer support, territory development, product expertise, and account management, while prosecutors will attempt to prove that compensation rewarded prohibited influence rather than fairly valued documented lawful services.
Internal Commission Records Could Connect the Corporate Layers
One alleged communication explained that a commission could be paid only when a provider office reported that insurance had paid, directly connecting representative compensation with reimbursements generated through the recruited medical practice’s skin-substitute claims.
Another commission report allegedly documented a $120,611.73 payment to one representative, including an $8,446.03 component tied to profits Protectus received from the provider invoice dividing the earlier $53,625.60 government reimbursement.
Prosecutors can align those records with claim dates, payer notices, provider deposits, company invoices, customer payments, commission approvals, and representative checks to argue that one coordinated financial cycle operated across several entities and relationships.
McMillan’s attorneys can demand the complete commission agreements, service descriptions, account histories, corrections, expenses, and surrounding communications, arguing that excerpts chosen for an indictment may omit evidence supporting lawful compensation or corporate separateness.
The Major Financial Figures Describe Related Categories
The indictment alleges approximately $268 million in government payments, approximately $174 million received by McMillan and Protectus, and approximately $94 million retained by providers as alleged kickbacks through the percentage arrangement during the charged period.
Those amounts appear to draw from the same reimbursement stream, so the company receipts and provider shares should not be added to the government-payment total as though Medicare, TRICARE, and CHAMPVA issued three separate sets of funds.
The approximately $27 million allegedly paid to sales representatives likewise came from the business side of the payment cycle after Protectus collections, rather than representing an additional category of claims paid directly by federal programs.
Accurate reporting must distinguish billed amounts, paid claims, supplier receipts, provider margins, representative commissions, operating expenses, personal proceeds, seized property, restitution, and forfeiture because each category answers a different financial and legal question.
The Nine Counts Target McMillan Through Three Legal Theories
Count One alleges a conspiracy to commit healthcare fraud, asserting that McMillan knowingly joined an agreement to obtain government-program money through materially false representations and claims allegedly induced by illegal remuneration involving skin-substitute products.
Count Two alleges a separate conspiracy to defraud the United States and pay federal-program kickbacks, focusing upon alleged obstruction of lawful Medicare administration and remuneration intended to induce reimbursable purchases, orders, arrangements, or recommendations.
Counts Three through Nine allege seven monetary transactions exceeding $10,000 in property derived from the charged conspiracies, provisions commonly described as transactional money laundering even though the indictment does not allege concealment as each transaction’s purpose.
Those counts identify transactions associated with residential property, a Lamborghini, a Cadillac Escalade, and a Cessna Citation aircraft between December 2021 and September 2025, using several accounts publicly described within the charging document.
The financial counts require transaction-specific tracing and knowledge evidence, preventing prosecutors from establishing every property allegation merely by proving that a Protectus company received substantial revenue from providers during the broader charged period.
Corporate Accounts and Personal Transactions Will Require Tracing
Several scheduled transactions allegedly originated from Protectus LLC accounts, while others came from accounts associated with McMillan or another business, creating tracing questions involving revenue sources, transfers, commingled balances, financing, and property ownership.
For each monetary count, prosecutors must show that more than $10,000 in criminally derived property entered the qualifying transaction, alongside the required knowledge and jurisdictional elements established under the applicable federal statute.
The defense may identify lawful product revenue, loans, savings, capital contributions, financing, unrelated deposits, legitimate operating income, or timing gaps that complicate the government’s attempt to trace alleged proceeds into selected valuable acquisitions.
Authorities also reported seizing approximately $35 million in assets, although seizure preserves disputed property during litigation and does not ultimately establish permanent forfeiture, final valuation, criminal source, net equity, or McMillan’s guilt alone.
What Prosecutors Must Prove About the Companies
The government must prove more than common ownership and substantial revenue, because lawful businesses routinely use multiple entities, employees, contracts, commissions, invoicing platforms, bank accounts, and reimbursement-support functions without deliberately creating criminal conspiracies.
Prosecutors will likely seek to demonstrate that the companies operated with a common unlawful purpose through repeated percentage invoices, no-cost denials, Box 19 guidance, reimbursement-triggered refunds, representative commissions, and McMillan’s alleged approvals or explanations.
They must also establish McMillan’s knowing participation in each charged conspiracy, separating intentional deception and prohibited inducement from regulatory ambiguity, administrative error, aggressive contracting, legitimate risk allocation, or employee conduct beyond his knowledge.
Corporate records may provide consistency across witnesses and years, but they can also help the defense when they show transparent terms, genuine services, actual product deliveries, conventional accounting, independent clinical decisions, or good-faith compliance efforts.
Potential Defense Arguments Concerning Entity Boundaries
Defense counsel may challenge the indictment’s collective use of “Protectus” by insisting that each company’s conduct, employees, contracts, accounts, and purpose be evaluated separately rather than attributed automatically to McMillan or every related entity.
Attorneys can contest whether Protectus Technologies invoices establish practices followed by Protectus LLC, whether employees possessed complete information, whether representative relationships differed, and whether provider agreements changed materially across jurisdictions or time periods.
They may also argue that providers retained independent medical judgment, products delivered genuine patient value, commercial terms allocated real reimbursement risks, and pricing instructions were interpreted reasonably within a complicated and evolving regulatory environment.
None of those possible defenses has been accepted merely because it may be raised, just as an indictment, a government press conference, a large reimbursement figure, and images of luxury property do not establish guilt.
Compliance Lessons for Multi-Entity Healthcare Businesses
Businesses operating through affiliated entities should document why each company exists, who has authority, where contracts belong, how intercompany transfers work, and which entity performs sales, product, billing, collection, or compliance functions.
Healthcare suppliers should independently review arrangements involving no upfront cost, complete denial protection, percentage invoices, guaranteed provider margins, distributor-managed claims, reimbursement-dependent refunds, or commissions that fluctuate with payments generated by recruited clinicians nationwide.
Every acquisition-price disclosure should reconcile contracts, invoices, discounts, rebates, credits, refunds, free goods, replacements, financing terms, denial policies, and side communications that may materially alter the provider’s ultimate obligation under the complete arrangement.
Compliance teams should trace representative transactions from product acquisition through shipment, application, claim preparation, price disclosure, payer adjudication, provider collection, supplier invoice, company receipt, representative commission, owner distribution, and later documented asset purchase.
When credible concerns emerge, organizations should preserve records, suspend questionable practices, obtain qualified healthcare counsel and forensic accounting assistance, evaluate repayment or disclosure obligations, and prevent transfers or communications that could create additional allegations.
Public Attention Has Focused on the Corporate Scale
An NBC 5 Dallas-Fort Worth report about the regional prosecutions highlighted McMillan’s alleged skin-substitute arrangement and the government’s luxury-asset seizures, illustrating how corporate complexity can be overshadowed by dramatic financial totals and memorable property descriptions.
That visibility can immediately pressure employees, providers, vendors, lenders, patients, and business partners who need accurate information about who was charged, which companies were named, and which allegations remain unresolved.
Amicus International Consulting’s crisis public-relations guidance emphasizes structured assessment, timely response, and disciplined messaging, principles that support lawful communications when technical healthcare allegations generate simplified headlines, stakeholder anxiety, and intense online discussion before trial.
Its reputation-rebuilding resources likewise recognize that credible recovery requires sustained public information, making it essential to distinguish an indictment from conviction, corporate receipts from personal income, seizure from forfeiture, and allegation from adjudicated fact.
No ethical communications strategy can erase authentic court proceedings, obstruct investigators, conceal assets, influence witnesses, or fabricate corporate explanations, but careful terminology can reduce avoidable misinformation while preserving the integrity of the legal process.
A Major Prosecution Within the 2026 National Takedown
The McMillan matter was announced during the 2026 National Health Care Fraud Takedown, which federal authorities said produced charges against 455 defendants across fifty-six districts involving more than $6.5 billion in alleged false claims.
Northern District of Texas prosecutors announced seven separate cases involving thirteen defendants and more than $365 million in collective alleged billing, making the approximately $268 million Protectus matter the largest individually disclosed local prosecution within that package.
The coordinated announcement does not merge unrelated defendants into one conspiracy, and allegations concerning laboratories, hospice services, test kits, neurological testing, medical equipment, or other wound-care defendants cannot establish any element against McMillan.
Investigators directly credited in the McMillan case include the Federal Bureau of Investigation, the health department inspector general, defense investigators, and the veterans department inspector general, reflecting the multiple federal programs allegedly affected.
What Happens Next in the Protectus Case
The prosecution will proceed through discovery, pretrial motions, expert analysis, asset litigation, possible negotiations, and potentially trial, requiring extensive review of corporate records, provider files, claims data, contracts, products, communications, and financial accounts.
Future filings may clarify the roles of individual companies, identify cooperating providers or representatives, narrow challenged claims, explain disputed pricing requirements, disclose additional property information, or reveal defenses concerning legitimate business and clinical activity.
Courts may separately determine whether restrained assets remain available for forfeiture, return to McMillan, or belong partly or entirely to lenders, co-owners, affiliated businesses, spouses, or other third parties possessing legally recognized interests.
Until McMillan enters a valid guilty plea or prosecutors prove every required element beyond a reasonable doubt, all healthcare-fraud, kickback, corporate-operation, monetary-transaction, seizure, and forfeiture allegations remain unresolved under the continuing presumption of innocence.